for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allena Pharmaceuticals Inc

ALNA.OQ

Latest Trade

4.79USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.34

 - 

11.54

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.79
Open
--
Volume
--
3M AVG Volume
1.30
Today's High
--
Today's Low
--
52 Week High
11.54
52 Week Low
3.34
Shares Out (MIL)
23.47
Market Cap (MIL)
100.67
Forward P/E
-2.13
Dividend (Yield %)
--

Latest Developments

More

Allena Pharmaceuticals Reports Q2 Loss Per Share $0.54

Allena Pharmaceuticals Reports Q1 Loss Per Share Of $0.55

Allena Pharmaceuticals Qtrly Net Loss Per Share $0.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allena Pharmaceuticals Inc

Allena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.

Industry

Biotechnology & Drugs

Contact Info

1 Newton Executive Park Ste 202

+1.617.4674577

http://www.allenapharma.com/

Executive Leadership

Alexey L. Margolin

Chairman of the Board, Co-Founder

Louis Brenner

President, Chief Executive Officer, Director

Edward Wholihan

Chief Financial Officer

Robert D. Alexander

Independent Director

Allene M. Diaz

Independent Director

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-4.800

2018

-1.720

2019(E)

-1.992
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
26.48
LT Debt To Equity (MRQ)
21.19
Return on Investment (TTM)
-67.86
Return on Equity (TTM)
-62.57

Latest News

Latest News

BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38

* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharmaceuticals Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $0.48

* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria

* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA

BRIEF-HBM BioCapital II reports 7.94 pct passive stake in Allena Pharma

* HBM BioCapital II LP reports 7.94 percent passive stake in Allena Pharmaceuticals Inc as of November 6, 2017 - SEC filing Source text: (http://bit.ly/2A4iWbx) Further company coverage:

BRIEF-Allena Pharmaceuticals shares open 14.3 pct below IPO price in debut

* Allena Pharmaceuticals shares open at $12 in debut on the NASDAQ versus IPO price of $14/shr Further company coverage:

IFR Americas ECM Pipeline

Allena Pharmaceuticals (US, biotech) – $74.6m IPO. 5.33m shares (100% prim) at $14.00 versus $14-$16 marketing. CS, JEFF, COWN. Algonquin Power & Utilities (Canada, utility) – C$500m Block. 37.8m shares (100% prim) at C$13.25 versus C$13.75 last sale. SCOT, CIBC, TD. Assembly...

BRIEF-Allena Pharmaceuticals prices IPO of 5.3 mln shares at $14 per share

* Allena pharmaceuticals, Inc. Announces pricing of initial public offering

BRIEF-Allena Pharmaceuticals sees IPO price range of $14-$16/shr

* Allena pharmaceuticals Inc sees IPO of up to 5.33 million shares of common stock to be priced between $14 and $16 per share - SEC filing Source text: [http://bit.ly/2zvbZf3] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up